Clinical evidence

Study 1: Resveratrol supports cardiovascular health

An insight article published in Nature journal redefines the role and mechanism of resveratrol in improving cardiovascular health. The authors, with the support of the peer-reviewed clinical trials and preclinical experiments, propose that the resveratrol shows its cardioprotective ability not only through its ability to reduce the circulating low-density lipoprotein cholesterol levels but also by preventing lipid oxidation, platelet aggregation, arterial vasodilation, and modulating the levels of lipids and lipoproteins. It reduces oxidative stress through its antioxidant activity and α-tocopherol regenerating ability. Resveratrol has not been shown to have any significant toxic effects even when consumed at higher doses

Ramprasath VR, Jones PJ. Anti-atherogenic effects of resveratrol. Eur. J. Clin. Nutr. 2010;64(7):660-668

Continue Reading

Study 2: Resveratrol supplementation improves lipid profile in subjects with dyslipidemia

A clinical study evaluated the effect of resveratrol supplementation on lipid profile in individuals with dyslipidemia. The study was a randomized double-blind, placebo-controlled trial in 71 dyslipidemic subjects. The subjects were administered with 100 mg/day of resveratrol for two months. The administration resulted in a significant decrease in total cholesterol (P = 0.04) and triacylglycerol (P = 0.04) levels in the serum when compared with the placebo group.

Simental-Mendía LE, Guerrero-Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial. Nutrition. 2019;58:7-10

Continue Reading

Study 3: Resveratrol reduces the neuroinflammation in subjects with Alzheimer’s disease

A randomized, placebo-controlled, double-blind study evaluated the efficacy of resveratrol to modulate neuroinflammation in 19 subjects with mild-moderate Alzheimer’s disease (AD). The subjects were supplemented with an oral dose of 1 g twice a day of resveratrol for 52 weeks; the changes in levels of inflammatory markers of cerebrospinal fluids (CSF) and activities of daily living (ADL) scores were measured as assessment parameters. At the end of the study period, resveratrol markedly reduced CSF matrix metalloprotease 9 and improved the levels of macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2. When compared to baseline resveratrol increased plasma matrix metalloprotease 10 and decreased IL-12P40, IL12P70, and RANTES. Also, the supplementation attenuated decline in mini-mental status examination (MMSE) scores, and change in ADL (ADCS-ADL). The study concluded that resveratrol modulated the neuroinflammation and induces adaptive immunity in the subjects with Alzheimer’s disease.

Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation. 2017;14(1):1

Continue Reading